784 related articles for article (PubMed ID: 35283215)
1. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
[TBL] [Abstract][Full Text] [Related]
2. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 vaccine in liver transplant recipients.
Toniutto P; Cussigh A; Cmet S; Bitetto D; Fornasiere E; Fumolo E; Fabris M; D'Aurizio F; Fabris C; Grillone L; Sartor A; Curcio F; Falleti E
Liver Int; 2023 Feb; 43(2):452-461. PubMed ID: 35661561
[TBL] [Abstract][Full Text] [Related]
4. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
[TBL] [Abstract][Full Text] [Related]
5. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
6. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
7. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
[TBL] [Abstract][Full Text] [Related]
10. Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort.
Zecca E; Rizzi M; Tonello S; Matino E; Costanzo M; Rizzi E; Casciaro GF; Manfredi GF; Acquaviva A; Gagliardi I; Calzaducca E; Mallela VR; D'Onghia D; Minisini R; Bellan M; Castello LM; Gavelli F; Avanzi GC; Patrucco F; Chiocchetti A; Pirisi M; Rigamonti C; Lilleri D; Sola D; Sainaghi PP
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016388
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients.
Toniutto P; Cussigh A; Cmet S; Fabris M; Curcio F; Bitetto D; Fornasiere E; Fumolo E; Falleti E
Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514981
[TBL] [Abstract][Full Text] [Related]
12. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
[TBL] [Abstract][Full Text] [Related]
13. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
14. SARS-COV-2 vaccine responses in renal patient populations.
Smith RM; Cooper DJ; Doffinger R; Stacey H; Al-Mohammad A; Goodfellow I; Baker S; Lear S; Hosmilo M; Pritchard N; Torpey N; Jayne D; Yiu V; Chalisey A; Lee J; Vilnar E; Cheung CK; Jones RB
BMC Nephrol; 2022 May; 23(1):199. PubMed ID: 35641961
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study.
Matsunami M; Suzuki T; Sugihara S; Toishi T; Nagaoka K; Fukuda J; Ohara M; Takanashi Y; Ochi A; Yashima J; Kuji H; Matsue K
Transplant Proc; 2022; 54(6):1483-1488. PubMed ID: 35868872
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 vaccine alleviates disease burden and severity in liver transplant recipients even with low antibody titers.
Khalaileh A; Imam A; Jammal A; Hakimian D; Amer J; Shafrir A; Milgrom Y; Massarwa M; Hazou W; Khader M; Safadi R
Hepatol Commun; 2023 Feb; 7(2):e0025. PubMed ID: 36724131
[TBL] [Abstract][Full Text] [Related]
17. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.
Tomiyama T; Suzuki R; Harada N; Tamura T; Toshida K; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Takeishi K; Itoh S; Kobayashi N; Ito H; Yoshio S; Kanto T; Yoshizumi T; Fukuhara T
Front Cell Infect Microbiol; 2023; 13():1197349. PubMed ID: 37260700
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
[TBL] [Abstract][Full Text] [Related]
19. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
